Increased PD‐1/PD‐L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never‐Smokers and Never‐Drinkers

Mathias Fiedler,Alisa Off,Andreas Gärtner,Gero Brockhoff,Jonas Eichberger,Maximilian Gottsauner,Johannes G. Schuderer,Michael Maurer,Richard J. Bauer,Michael Gerken,Torsten E. Reichert,Tobias Ettl,Florian Weber
DOI: https://doi.org/10.1002/hed.27981
2024-10-29
Head & Neck
Abstract:Background This study aimed to explore the disparities in PD‐1 and PD‐L1 expression among oral squamous cell carcinomas (OSCCs) in individuals categorized as never‐smokers/never‐drinkers versus smokers/drinkers. Methods Immunohistochemical staining for PD‐1 and PD‐L1, along with PDCD1LG2/cen9 dual color probe analysis, was conducted on 130 OSCC specimens from both smoker/drinker and never‐smoker/never‐drinker cohorts. Associations between smoking/drinking status, clinicopathologic data, immunohistochemical antibody expression, fluorescence in situ hybridization, and survival outcomes were assessed. Results OSCC in never‐smokers/never‐drinkers exhibited significantly elevated PD‐1 expression (p = 0.003), increased PD‐L1‐TPS expression (p = 0.044), and elevated PD‐L1‐CPS expression (p
surgery,otorhinolaryngology
What problem does this paper attempt to address?